Cannara Biotech Balance Sheet Health
Financial Health criteria checks 3/6
Cannara Biotech has a total shareholder equity of CA$88.0M and total debt of CA$47.7M, which brings its debt-to-equity ratio to 54.2%. Its total assets and total liabilities are CA$154.7M and CA$66.8M respectively. Cannara Biotech's EBIT is CA$7.6M making its interest coverage ratio 1.6. It has cash and short-term investments of CA$6.6M.
Key information
54.2%
Debt to equity ratio
CA$47.68m
Debt
| Interest coverage ratio | 1.6x |
| Cash | CA$6.62m |
| Equity | CA$87.95m |
| Total liabilities | CA$66.77m |
| Total assets | CA$154.72m |
Recent financial health updates
These 4 Measures Indicate That Cannara Biotech (CVE:LOVE) Is Using Debt Extensively
Oct 29
Does Cannara Biotech (CVE:LOVE) Have A Healthy Balance Sheet?
Jul 14Is Cannara Biotech (CVE:LOVE) A Risky Investment?
Jul 29Here's Why Cannara Biotech (CVE:LOVE) Has A Meaningful Debt Burden
Jan 26Cannara Biotech (CVE:LOVE) Has A Somewhat Strained Balance Sheet
Dec 10Here's Why Cannara Biotech (CSE:LOVE) Can Afford Some Debt
Mar 16Recent updates
Benign Growth For Cannara Biotech Inc. (CVE:LOVE) Underpins Its Share Price
Nov 26These 4 Measures Indicate That Cannara Biotech (CVE:LOVE) Is Using Debt Extensively
Oct 29Cannara Biotech Inc.'s (CVE:LOVE) 33% Price Boost Is Out Of Tune With Earnings
Aug 22Cannara Biotech (CVE:LOVE) Shareholders Will Want The ROCE Trajectory To Continue
Aug 21Does Cannara Biotech (CVE:LOVE) Have A Healthy Balance Sheet?
Jul 14Cannara Biotech Inc.'s (CVE:LOVE) Prospects Need A Boost To Lift Shares
May 09Here's Why We Think Cannara Biotech (CVE:LOVE) Might Deserve Your Attention Today
Feb 28Investor Optimism Abounds Cannara Biotech Inc. (CVE:LOVE) But Growth Is Lacking
Jan 24Cannara Biotech's (CVE:LOVE) Earnings May Just Be The Starting Point
Dec 18Is Cannara Biotech (CVE:LOVE) A Risky Investment?
Jul 29Cannara Biotech Inc.'s (CVE:LOVE) Business Is Yet to Catch Up With Its Share Price
Apr 10Here's Why Cannara Biotech (CVE:LOVE) Has A Meaningful Debt Burden
Jan 26Cannara Biotech's (CVE:LOVE) Earnings Aren't As Good As They Appear
Jan 27Cannara Biotech (CVE:LOVE) Has A Somewhat Strained Balance Sheet
Dec 10Here's Why Cannara Biotech (CSE:LOVE) Can Afford Some Debt
Mar 16Can You Imagine How Cannara Biotech's (CSE:LOVE) Shareholders Feel About The -6.5% Share Price Increase?
Jan 22
Have Insiders Been Buying Cannara Biotech Inc. (CSE:LOVE) Shares?
Dec 18Financial Position Analysis
Short Term Liabilities: LOVE's short term assets (CA$67.5M) exceed its short term liabilities (CA$27.0M).
Long Term Liabilities: LOVE's short term assets (CA$67.5M) exceed its long term liabilities (CA$39.8M).
Debt to Equity History and Analysis
Debt Level: LOVE's net debt to equity ratio (46.7%) is considered high.
Reducing Debt: LOVE's debt to equity ratio has increased from 25.1% to 54.2% over the past 5 years.
Debt Coverage: LOVE's debt is well covered by operating cash flow (22.4%).
Interest Coverage: LOVE's interest payments on its debt are not well covered by EBIT (1.6x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 03:09 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/08/31 |
| Annual Earnings | 2024/08/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cannara Biotech Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|